{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-007048","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.589838+00:00","generated_at":"2026-06-26T00:45:58.866478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront","bullets":["Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.","Novartis license option: $54M upfront, up to $1.5B milestones for TRACER capsids on up to 5 CNS targets.","Alfred Sandrock appointed CEO (March 2022); Robin Swartz promoted to COO.","TRACER AAV9 capsid yields 50-60x better brain transduction in mice/macaques vs AAV9; AAV5 capsid 20x vs AAV9.","Preclinical data: vectorized HER2 antibody reduces tumor burden; GBA1, SOD1, anti-tau programs advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-007048","json":"https://secwatch.observer/filing/0001558370-22-007048.json","markdown":"https://secwatch.observer/filing/0001558370-22-007048.md","text":"https://secwatch.observer/filing/0001558370-22-007048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/0001558370-22-007048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/vygr-20220504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:45:58.866478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}